(Q50965805)

26 March 2018

title

Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis. (English)

1 reference

26 March 2018

0 references

6

1 reference

26 March 2018

Henrik Zetterberg

4

object named as

Henrik Zetterberg

1 reference

26 March 2018

7

Anders Svenningsson

1 reference

26 March 2018

2

Clas Malmeström

1 reference

26 March 2018

author name string

Markus Axelsson

1

1 reference

26 March 2018

Martin Gunnarsson

3

1 reference

26 March 2018

Peter Sundström

5

1 reference

26 March 2018

publication date

23 May 2013

1 reference

26 March 2018

Multiple Sclerosis Journal

published in

1 reference

26 March 2018

volume

20

1 reference

26 March 2018

issue

1

1 reference

26 March 2018

page(s)

43-50

1 reference

26 March 2018

Inflammation, demyelination, neurodegeneration and neuroprotection in the pathogenesis of multiple sclerosis

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1352458513490544

Treatment of multiple sclerosis: current concepts and future perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513490544

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513490544

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513490544

Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513490544

Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513490544

Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513490544

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513490544

Benefit of interferon beta-1a on MSFC progression in secondary progressive MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513490544

Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513490544

MRI in multiple sclerosis: a review of the current literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513490544

Association between pathological and MRI findings in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513490544

Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513490544

Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513490544

Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513490544

Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513490544

Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513490544

Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513490544

Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513490544

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513490544

Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513490544

A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513490544

A sensitive ELISA for glial fibrillary acidic protein: application in CSF of adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513490544

Defining the clinical course of multiple sclerosis: Results of an international survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513490544

Neurofilament protein in cerebrospinal fluid: a potential marker of activity in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513490544

Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513490544

MRI as an outcome in multiple sclerosis clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513490544

21 January 2018

Identifiers

DOI

10.1177/1352458513490544

1 reference

26 March 2018

1 reference

26 March 2018